Hemopoietic cell transplantation for the myelodysplastic syndromes

Archivum Immunologiae et Therapiae Experimentalis

Volumn 53, Issue 4, 2005, Pages 297-307

  Scott, Bart L ^a,b   Deeg, H Joachim ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Conditioning regimens; Hemopoietic cell transplantation; MDS; Prognostic scoring systems

Indexed keywords

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CONDITIONING; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; STEM CELL;

AGED; ALLELES; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MARKOV CHAINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; STEM CELLS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 31944439788     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Anderson J. E., Appelbaum F. R., Schoch G., Gooley T., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Chauncey T., Clift R. A., Deeg H. J., Doney K., Flowers M., Hansen J. A., Martin P. J., Matthews D. C., Nash R. A., Sanders J. E., Shulman H., Sullivan K. M., Witherspoon R. P. and Storb R. (1996): Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J. Clin. Oncol., 14, 220-226.
2. Appelbaum F. R. and Anderson J. (1998): Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 12 (suppl. 1), S25-S29.
3. Appelbaum F. R., Barrall J., Storb R., Fisher L. D., Schoch G., Ramberg R. E., Shulman H., Anasetti C., Bearman S. I., Beatty P., Bensinger W. I., Buckner C. D., Clift R. A., Hansen J. A., Martin P., Petersen F. B., Sanders J. E., Singer J., Stewart P., Sullivan K. M., Witherspoon R. P. and Thomas E. D. (1990): Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann. Intern. Med., 112, 590-597.
4. Arnold R., de Witte T., van Biezen A., Hermans J., Jacobsen N., Runde V., Gratwohl A. and Apperley J. F. (1998): Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant., 21, 1213-1216.
5. Bader P., Klingebiel T., Schaudt A., Theurer-Mainka U., Handgretinger R., Lang P., Niethammer D. and Beck J. F. (1999): Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia, 13, 2079-2086.
6. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. and The French-American-British (FAB) Co-Operative Group (1982): Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 51, 189-199.
7. Bethge W. A., Hegenbart U., Stuart M. J., Storer B. E., Maris M. B., Flowers M. E., Maloney D. G., Chauncey T., Bruno B., Agura E., Forman S. J., Blume K. G., Niederweiser D., Storb R. and Sandmaier B. M. (2004): Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood, 103, 790-795.
8. Bornhäuser M., Storer B., Slattery J. T., Appelbaum F. R., Deeg H. J., Hansen J., Martin P. J., McDonald G. B., Nichols G., Radich J., Woolfrey A., Jenke A., Schleyer E., Thiede C., Ehninger G. and Anasetti C. (2003): Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood, 102, 820-826.
9. Carella A. M., Champlin R., Slavin S., McSweeney P. and Storb R. (2000): Mini-allografts: ongoing trials in humans. Bone Marrow Transplant., 25, 345-350.
10. Castagna L., El Weshi A., Bourhis J. H., Ribrag V., Naccache P., Vantelon J. M., Brault P. and Pico J. L. (1998): Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted frone marrow transplantation (TD-BMT). Br. J. Haematol., 103, 284-285.
11. Castro-Malaspina H., Harris R. E., Gajewski J., Ramsay N., Collins R., Dharan B., King R. and Deeg H. J. (2002): Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood, 99, 1943-1951.
12. Cutler C. S., Lee S. J., Greenberg P., Deeg H. J., Pérez W. S., Anasetti C., Bolwell B. J., Cairo M. S., Gale R. P., Klein J. P., Lazarus H. M., Liesveld J. L., McCarthy P. L., Milone G. A., Rizzo J. D., Schultz K. R., Trigg M. E., Keating A., Weisdorf D. J., Antin J. H. and Horowitz M. M. (2004): A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 104, 579-585.
13. Deeg H. J., Appelbaum F. R., Storer B., Cassarella M., Scott B., McDonald G. and Storb R. (2004): Reduced incidence of acute and chronic graft-versus-host disease (GvHD) without increased relapse in patients with high-risk myeloid disorders given thymoglobulin (THY) as part of the transplant conditioning regimen: a dose finding study. Blood, 104 (part 1), 56a, 181(abstract).
14. Deeg H. J., Jiang P. Y., Holmberg L. A., Scott B., Petersdorf E. W. and Appelbaum F. R. (2004): Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk. Res., 28, 1177-1180.
15. Deeg H. J., Shulman H. M., Anderson J. E., Bryant E. M., Gooley T. A., Slattery J. T., Anasetti C., Fefer A., Storb R. and Appelbaum F. R. (2000): Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood, 95, 1188-1194.
16. Deeg H. J., Storer B., Slattery J. T., Anasetti C., Doney K. C., Hansen J. A., Kiem H.-P., Martin P. J., Petersdorf E., Radich J. P., Sanders J. E., Shulman H. M., Warren E. H., Witherspoon R. P., Bryant E. M., Chauncey T. R., Getzendaner L., Storb R. and Appelbaum F. R. (2002): Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood, 100, 1201-1207.
17. de Lima M., Anagnostopoulos A., Munsell M., Shahjahan M., Ueno N., Ippoliti C., Andersson B. S., Gajewski J., Couriel D., Cortes J., Donato M., Neumann J., Champlin R. and Giralt S. (2004): Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood, 104, 865-872.
18. de Lima M., Couriel D., Thall P. F., Wang X., Madden T., Jones R., Shpall E. J., Shahjahan M., Pierre B., Giralt S., Korbling M., Russell J. A., Champlin R. E. and Andersson B. S. (2004): Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 104, 857-864.
19. Depil S., Deconinck E., Milpied N., Sutton L., Witz F., Jouet J. P., Damaj G. and Yakoub-Agha I. (2004): Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant., 33, 531-534.
20. de Witte T., Suciu S., Verhoef G., Labar B., Archimbaud E., Aul C., Selleslag D., Ferrant A., Wijermans P., Mandelli F., Amadori S., Jehn U., Muus P., Boogaerts M., Zittoun R., Gratwohl A., Zwierzina H., Hagemeijer A. and Willemze R. (2001): Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood, 98, 2326-2331.
21. de Witte T., van Biezen A., Hermans J., Labopin M., Runde V., Or R., Meloni G., Mauri S. B., Carella A., Apperley J., Gratwohl A. and Laporte J.-P. (1997): Autologous hone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood, 90, 3853-3857.
22. Friedberg J. W., Neuberg D., Stone R. M., Alyea E., Jallow H., LaCasce A., Mauch P. M., Gribben J. G., Ritz J., Nadler L. M., Soiffer R. J. and Freedman A. S. (1999): Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol., 17, 3128-3135.
23. Greenberg P., Cox C., LeBeau M. M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G. and Bennett J. (1997): International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088
24. (published erratum appears in Blood, 1998; 91: 1100).
25. Guardiola P., Runde V., Bacigalupo A., Ruutu T., Locatelli F., Boogaerts M. A., Pagliuca A., Cornelissen J. J., Schouten H. C., Carreras E., Finke J., van Biezen A., Brand R., Niederwieser D., Gluckman E., de Witte T. M. and Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group (2002): Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood, 99, 4370-4378.
26. Ho A. Y., Pagliuca A., Kenyon M., Parker J. E., Mijovic A., Devereux S. and Mufti G. J. (2004): Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood, 104, 1616-1623.
27. Jurado M., Deeg H. J., Storer B., Anasetti C., Anderson J. E., Bryant E., Chauncey T., Doney K., Flowers M. E., Hansen J., Martin P. J., Nash R. A., Petersdorf E., Radich J., Sale G., Sandmaier B. M., Storb R., Wade J., Witherspoon R. and Appelbaum F. R. (2002): Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol. Blood Marrow Transplant., 8, 161-169.
28. Kroger N., Bornhauser M., Ehninger G., Schwerdtfeger R., Biersack H., Sayer H. G., Wandt H., Schafer-Eckardt K., Beyer J., Kiehl M. and Zander A. R. (2003): Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann. Hematol., 82, 336-342.
29. Kroger N., Schetelig J., Zabelina T., Kruger W., Renges H., Stute N., Schrum J., Kabisch H., Siegert W. and Zander A. R. (2001): A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant., 28, 643-647.
30. List A., Beran M., DiPersio J., Slack J., Vey N., Rosenfeld C. S. and Greenberg P. (2003): Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia, 17, 1499-1507.
31. Maschek H., Georgii A., Kaloutsi V., Werner M., Bandecar K., Kressel M.-G., Choritz H., Freund M. and Hufnagl D. (1992): Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur. J. Haematol., 48, 208-214.
32. McSweeney P. A. and Storb R. (1999): Mixed chimerism: preclinical studies and clinical applications. Biol. Blood Marrow Transplant., 5, 192-203.
33. Micallef I. N., Lillington D. M., Apostolidis J., Amess J. A., Neat M., Matthews J., Clark T., Foran J. M., Salam A., Lister A. and Rohatiner A. Z. (2000): Therapy-related myelodsyplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J. Clin. Oncol., 18, 947-955.
34. Molldrem J. J., Leifer E., Bahceci E., Saunthararajah Y., Rivera M., Dunbar C., Liu J., Nakamura R., Young N. S. and Barrett A. J. (2002): Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome. Ann. Intern. Med., 137, 156-163.
35. Nevill T. J., Fung H. C., Shepherd J. D., Horsman D. E., Nantel S. H., Klingemann H. G., Forrest D. L., Toze C. L., Sutherland H. J., Hogge D. E., Naiman S. C., Le A., Brockington D. A. and Barnett M. J. (1998): Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood, 92, 1910-1917.
36. O'Donnell M. R., Long G. D., Parker P. M., Niland J., Nademanee A., Amylon M., Chao N., Negrin R. S., Schmidt G. M., Slovak M. L., Smith E. P., Snyder D. S., Stein A. S., Traweek T., Blume K. G. and Forman S. J. (1995): Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J. Clin. Oncol., 13, 2973-2979.
37. Oosterveld M., Suciu S., Verhoef G., Labar B., Belhabri A., Aul C., Selleslag D., Ferrant A., Wijermans P., Mandelli F., Amadori S., Jehn U., Muus P., Zittoun R., Hess U., Anak O., Beeldens F., Willemze R. and de Witte T. (2003): The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia, 17, 859-868.
38. Parker J. E., Shafi T., Pagliuca A., Mijovic A., Devereux S., Potter M., Prentice H. G., Garg M., Yin J. A., Byrne J., Russell N. H. and Mufti G. J. (2002): Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br. J. Haematol., 119, 144-154.
39. Ratanatharathorn V., Karanes C., Uberti J., Lum L. G., de Planque M. M., Schultz K. R., Cronin S., Dan M. E., Mohamed A., Hussein M. and Sensenbrenner L. L. (1993): Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood, 81, 2194-2199.
40. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., du Rand M., Kaspar C., Goldberg C., Loew J., Dar S., Gezer S., Venugopal P. and Zeldis J. (2001): Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 98, 958-965.
41. Runde V., de Witte T., Arnold R., Gratwohl A., Hermans J., van Biezen A., Niederwieser D., Labopin M., Walter-Noel M. P., Bacigalupo A., Jacobsen N., Ljungman P., Carreras E., Kolb H. J., Aul C. and Apperley J. (1998): Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant., 21, 255-261.
42. Russell J. A., Tran H. T., Quinlan D., Chaudhry A., Duggan P., Brown C., Stewart D., Ruether J. D., Morris D., Glick S., Gyonyor E. and Andersson B. S. (2002): Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol. Blood Marrow Transplant., 8, 468-476.
43. Scott B. L., Chyou F. and Deeg H. J. (2004): Does marrow fibrosis influence post-transplant outcome in patients with myelodysplastic syndrome (MDS)? Exp. Hematol., 32 (suppl. 1), 47-48.
44. Scott B. L., Maris M., Sandmaier B., Storer B., Chauncey T., Maloney D. G., Sorror M., Storb R. and Deeg H. J. (2004): Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multinlineage dysplasia following MDS (tAML). Blood, 104 (part 1), 638a (abstract).
45. Scott B. L., Storer B., Loken M., Storb R., Appelbaum F. R. and Deeg H. J. (2005): Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol. Blood Marrow Transplant, 11, 65-73.
46. Shiobara S., Nakao S., Ueda M., Yamazaki H., Takahashi S., Asano S., Yabe H., Kato S., Imoto S., Maruta A., Yoshida T., Gondo H., Morishima Y. and Kodera Y. (2000): Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant., 26, 769-774.
47. Sierra J., Pérez W. S., Rozman C., Carreras E., Klein J. P., Rizzo J. D., Davies S. M., Lazarus H. M., Bredeson C. N., Marks D. I., Canals C., Boogaerts M. A., Goldman J., Champlin R. E., Keating A., Weisdorf D. J., de Witte T. M. and Horowitz M. M. (2002): Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood, 100, 1997-2004.
48. Silverman L. R., Demakos E. P., Peterson B. L., Kornblith A. B., Holland J. C., Odchimar-Reissig R., Stone R. M., Nelson D., Powell B. L., DeCastro C. M., Ellerton J., Larson R. A., Schiffer C. A. and Holland J. F. (2002): Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol., 20, 2429-2440.
49. Sobecks R. M., Le Beau M. M., Anastasi J. and Williams S. F. (1999): Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant., 23, 1161-1165.
50. st century. Transplant. Proc., 32, 2548-2549.
51. Stuart M. J., Cao T. M., Sandmaier B. M., Hegenbart U., Maris M., Agura E., Chauncey T. R., Maloney D. G., Pulsipher M. A., Wong R., Niederwieser D. W., Blume K. G. and Storb R. F. (2003): Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). Blood, 102 (part 1), 185a (abstract).
52. Vardiman J. W., Harris N. L. and Brunning R. D. (2002): The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292-2302.
53. Wattel E., Solary E., Leleu X., Dreyfus F., Brion A., Jouet J. P., Hoang-Ngoc L., Maloisel F., Guerci A., Rochant H., Gratecos N., Casassus P., Janvier M., Brice P., Lepelley P. and Fenaux P. (1999): A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia, 13, 524-529.
54. Weisdorf D. J., Anasetti C., Antin J. H., Kernan N. A., Kollman C., Snyder D., Petersdorf E., Nelson G. and McGlave P. (2002): Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood, 99, 1971-1977.
55. Wells D. A., Benesch M., Loken M. R., Vallejo C., Myerson D., Leisenring W. M. and Deeg H. J. (2003): Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood, 102, 394-403.
56. Witherspoon R. P., Deeg H. J., Storer B., Anasetti C., Storb R. and Appelbaum F. R. (2001): Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J. Clin. Oncol., 19, 2134-2141.
57. Yakoub-Agha I., de La Salmonière P., Ribaud P., Sutton L., Wattel E., Kuentz M., Jouet J. P., Mark G., Milpied N., Deconinck E., Gratecos N., Leporrier M., Chabbert I., Caillot D., Damaj G., Dauriac C., Dreyfus F., François S., Molina L., Tanguy M. L., Chevret S. and Gluckman E. (2000): Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J. Clin. Oncol., 18, 963-971.